Browse Vascular endothelial growth factor topic

Subtopics (8) Analysis Conferences, meetings and seminars Drug therapy Health aspects Models Physiological aspects Prevention Research

Articles 1-64 out of 64 article(s) Title Author Type Date Words AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting. Nov 17, 2009 651 Mean platelet volumes in babies of preeclamptic mothers/ Preeklamptik anne bebeklerinde ortalama trombosit hacimleri. Akcan, A. Baris; Oygucu, Seyhan Erisir; Ozel, Deniz; Oygur, Nihal Clinical report Sep 1, 2009 2024 Researchers discover link between organ transplantation and increased cancer risk. Report Aug 1, 2009 450 First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion. Jul 23, 2009 1047 Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. Report Jul 1, 2009 226 Two Newly-Published Scientific Papers Showed That the Steroid Used in Company's Iluvien Device Acted as Both a VEGF Inhibitor and Neuroprotectant. Jun 15, 2009 1007 Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites. Clinical report Jun 11, 2009 1765 BAYER/REGENERON EXTEND PROGRAM FOR VEGF TRAP-EYE. Jun 1, 2009 950 AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer. Apr 21, 2009 884 AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer. Mar 10, 2009 860 AVEO Pharmaceuticals' Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer. Feb 25, 2009 1283 AVEO Initiates Phase 1b/2a Combination Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Advanced Breast Cancer. Feb 19, 2009 910 VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting. Sep 28, 2008 1735 Presentations on the Mechanism of Action of VEGFb(TM), the World's only "Triple Action Angiogenesis Modulator," Support VEGFb's Role as a Promising Treatment for Solid Cancers, Macular Degeneration, and Other Diseases. Sep 2, 2008 1110 Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration. Aug 19, 2008 1393 Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer Commences. Aug 13, 2008 1078 PhiloGene, Inc. Announces that VEGFb(TM) has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma. Jul 22, 2008 873 Angiogenesis and the tumour microenvironment. Almendro, Vanessa; Gascon, Pere Report Jun 1, 2008 2865 Anti-angiogenic agents in colorectal cancer. Guillen-Ponce, Carmen; Carrato, Alfredo Report Jun 1, 2008 4806 Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology. May 21, 2008 1854 Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration. Apr 28, 2008 1736 PhiloGene Inc. Announces Revolutionary Advances in the Treatment of Cancer and Macular Degeneration. Apr 22, 2008 974 AVEO Pharmaceuticals' Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers. Apr 14, 2008 1043 Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types. Apr 13, 2008 1644 New Clinical Data on AVEO Pharmaceuticals' Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting. Apr 8, 2008 586 AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma. Jan 31, 2008 699 Taspine isolated from Radix et Rhizoma Leonticis inhibits growth of human umbilical vein endothelial cell (HUVEC) by inducing its apoptosis. Zhang, Yanmin; He, Langchong; Zhou, Yali Jan 1, 2008 4115 Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as Avastin(R) in Preclinical Cancer Models. Nov 19, 2007 360 Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease. Nov 6, 2007 780 Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration. Oct 1, 2007 1410 Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis. Aug 23, 2007 504 Adnexus Therapeutics to Present Data on Adnectin Product Candidate, CT-322, at Gordon Research Conference. Conference news Aug 20, 2007 378 Regeneron Receives $20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD. Aug 13, 2007 736 Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD). Aug 3, 2007 1450 Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting. Jun 2, 2007 1921 VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting. May 9, 2007 1384 Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine. Apr 23, 2007 407 Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322. Apr 17, 2007 804 Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration. Clinical report Mar 27, 2007 1331 Regeneron Announces VEGF Trap Clinical Update. Feb 12, 2007 371 AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors. Nov 4, 2006 1511 CoGenesys announces worldwide growth factor license agreement with Vegenics. Aug 1, 2006 574 First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials; Anti-Cancer Therapeutic is a First in a Broadly Applicable, Innovative Class of Targeted Therapeutics. Jun 21, 2006 637 OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting. May 4, 2006 1781 Regeneron Reports Positive Phase 1 Data for the VEGF Trap in Age-Related Macular Degeneration; Preliminary Results Show Improvements in Vision and Retinal Swelling; VEGF Trap Was Well Tolerated at All Dose Levels. May 1, 2006 1238 Albert Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Harold F. Dvorak, M.D. Mar 31, 2006 755 Systemic Safety Profile of Macugen(R) (pegaptanib sodium injection) Maintained Throughout Two Years with No Increased Risk of Cardiovascular Events. Feb 24, 2006 1639 Regeneron's VEGF Trap Demonstrates Positive Preliminary Results in Patients with Age-Related Macular Degeneration; Phase 1 Preliminary Results to Be Presented at the Angiogenesis 2006 Meeting Sponsored by Bascom Palmer Eye Institute. Feb 2, 2006 677 Signet announces the availability of monoclonal antibodies EGFR, clone F4 and VEGF, clone VG-1. Feb 1, 2006 251 SANOFI-AVENTIS/REGENERON EXPAND VEGF TRAP PACT TO JAPAN. Feb 1, 2006 392 Agreements. Feb 1, 2006 871 Sanofi-Aventis and Regeneron Pharmaceuticals Expand Their VEGF Trap Oncology Collaboration to Japan. Dec 22, 2005 803 MethylGene Updates on Multi-Targeted Kinase Inhibitor Program, Discloses Additional Anti-Angiogenic Targets. Nov 16, 2005 672 INCLONE/UCB TO DEVELOP/COMMERCIALIZE CDP-791. Oct 1, 2005 512 Lowered salivary proteins are linked to depression. Splete, Heidi Brief article Oct 1, 2005 213 Corautus announces collaboration and licensing agreement for treatment of diabetic neuropathy with VEGF-2. Jul 1, 2005 660 Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV. Jun 1, 2005 1022 The effects of various inhibitors on vascular endothelial growth factor and peroxynitrite in retina endothelial cells. Clare, Jeremy Jan 1, 2005 181 Peregrine announces patent grant for angiogenesis therapy. Feb 1, 2004 611 Jack Gardiner: patient number one. Zipes, Douglas Brief Article Feb 1, 2003 277 Gene trials for diabetic neuropathy. SerVaas, Cory Dec 1, 2002 314 CORONARY GENE THERAPY UPDATE. Oct 1, 2000 229 Increased Expression of Vascular Endothelial Growth Factor and Angiogenesis in the Early Stage of Multistep Hepatocarcinogenesis. Park, Young Nyun; Kim, Young-Bae; Yang, Kyung Moo; Park, Chanil Jul 1, 2000 3495 CARDIAC GENE THERAPY: MORE SUCCESS STORIES. Perry, Patrick Mar 1, 2000 3099